title: Reply to Harrington et al.
authors.affiliation: Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda.
authors.forename: Sreetha
authors.initials: S
authors.lastname: Sidharthan
authors.affiliation: Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda.
authors.forename: Anita
authors.initials: A
authors.lastname: Kohli
authors.affiliation: Institute of Human Virology, University of Maryland, Baltimore Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Shyam
authors.initials: S
authors.lastname: Kottilil
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019562:Viral Load / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents